Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, May 17, 2024
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
[ Fri, May 17th 2024
] - WOPRAI
Thu, May 16, 2024
[ Thu, May 16th 2024
] - WOPRAI
[ Thu, May 16th 2024
] - WOPRAI
Tim Moore Maintained (SONN) at Strong Buy with Decreased Target to $56 on, May 16th, 2024
Tim Moore of EF Hutton, Maintained "Sonnet BioTherapeutics Holdings, Inc." (SONN) at Strong Buy with Decreased Target from $88 to $56 on, May 16th, 2024.
Tim has made no other calls on SONN in the last 4 months.
There is 1 other peer that has a rating on SONN. Out of the 1 peers that are also analyzing SONN, 0 agree with Tim's Rating of Hold.
This is the rating of the analyst that currently disagrees with Tim
- Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Decreased Target to $240 on, Thursday, February 15th, 2024
